Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of CNTO 1275 in Moderate to Severe Plaque Psoriasis
2005-003530-17Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Feb 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing CNTO 1275 with Placebo (2 arms). Primary endpoint: PASI 75 response at Week 12. Started Feb 2006; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2005-003530-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003530-17.